TIME Breast Cancer

Treating Cancer With A Malaria Drug

A drug that treats malaria may make breast cancer tumors more responsive to treatment

An inexpensive malaria could be the answer for some women who are not responding to their cancer treatment, according to a promising but preliminary animal study.

In a recent study published in Clinical Cancer Research, researchers discovered the anti-malaria drug hydroxychloroquine (HCQ) can actually reverse drug resistance to the common breast cancer drug, tamoxifen. The researchers inserted cancerous tumors into mice with serious postmenopausal estrogen receptor-positive (ER+) breast cancer. ER+ breast cancers are some of the most common, and are often treated with tamoxifen. However, about 50% of women who are treated with tamoxifen won’t respond to the drug or become resistant to it.

HCQ is a drug that was originally developed to treat malaria, but it’s also used to treat diseases like lupus and arthritis. The researchers added HCQ to the mice’s treatment with tamoxifen and discovered that the malaria did in fact increase tumor responsiveness to the breast cancer drug.

How does it work? The reason some woman become resistant to tamoxifen is that a “pro-survival” cell pathway in the breast cancer cells becomes switched. HCQ turns off the modified cell pathway, which helps prevent resistance to tamoxifen.

It’s still early to draw any conclusions on how HCQ could be used clinically for cancer, and so far, research has been reserved in mice. Still, the researchers think it’s encouraging that there may be a solution for women not responding to cancer drugs.

Tap to read full story

Your browser is out of date. Please update your browser at http://update.microsoft.com


Dear TIME Reader,

As a regular visitor to TIME.com, we are sure you enjoy all the great journalism created by our editors and reporters. Great journalism has great value, and it costs money to make it. One of the main ways we cover our costs is through advertising.

The use of software that blocks ads limits our ability to provide you with the journalism you enjoy. Consider turning your Ad Blocker off so that we can continue to provide the world class journalism you have become accustomed to.

The TIME Team